Macrophage-based approaches for cancer immunotherapy
Adoptive cell therapy with genetically modified T cells has generated exciting outcomes in
hematologic malignancies, but its application to solid tumors has proven challenging. This …
hematologic malignancies, but its application to solid tumors has proven challenging. This …
[HTML][HTML] Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …
Current and future perspectives of PD‐1/PDL‐1 blockade in cancer immunotherapy
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has
yielded great success in recent years. Among immunotherapeutic agents, immune …
yielded great success in recent years. Among immunotherapeutic agents, immune …
[HTML][HTML] The force awakens: metastatic dormant cancer cells
SY Park, JS Nam - Experimental & Molecular Medicine, 2020 - nature.com
Recurrent cancer that spreads to distant sites is the leading cause of disease-related death
among cancer patients. Cancer cells are likely to disseminate during cancer progression …
among cancer patients. Cancer cells are likely to disseminate during cancer progression …
[HTML][HTML] Targeting immune checkpoints in hematological malignancies
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
[HTML][HTML] Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies
Abstract Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen
receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking …
receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking …
Engineering next-generation CAR-T cells: overcoming tumor hypoxia and metabolism
TA Gao, YY Chen - Annual review of chemical and biomolecular …, 2022 - annualreviews.org
T cells engineered to express chimeric antigen receptors (CARs) have shown remarkable
success in treating B-cell malignancies, reflected by multiple US Food and Drug …
success in treating B-cell malignancies, reflected by multiple US Food and Drug …
[HTML][HTML] TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells
Acute myeloid leukemia (AML) is initiated and sustained by a hierarchy of leukemia stem
cells (LSCs), and elimination of this cell population is required for curative therapies. Here …
cells (LSCs), and elimination of this cell population is required for curative therapies. Here …
[HTML][HTML] Mechanisms of CAR T cell exhaustion and current counteraction strategies
X Zhu, Q Li, X Zhu - Frontiers in Cell and Developmental Biology, 2022 - frontiersin.org
The functional state of chimeric antigen receptor T (CAR T) cells determines their efficacy in
vivo. Exhausted CAR T cells exhibit decreased proliferative capacity, impaired anti-tumor …
vivo. Exhausted CAR T cells exhibit decreased proliferative capacity, impaired anti-tumor …
[HTML][HTML] Engineering induced pluripotent stem cells for cancer immunotherapy
Simple Summary Induced pluripotent stem cells (iPSCs) that can be genetically engineered
and differentiated into different types of immune cells, providing an unlimited resource for …
and differentiated into different types of immune cells, providing an unlimited resource for …